NCT06991790 2025-05-28
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
Peking University Cancer Hospital & Institute
Recruiting
Peking University Cancer Hospital & Institute
Fudan University